Related Experiment Videos

[New trends in the therapy of cryptococcosis in AIDS patients]

A Parisi1, A Malfitano, R Bruno

  • 1Divisione di Malattie Infettive e Tropicali, Universita degli Studi di Pavia-IRCCS, Policlinico San Matteo.

Le Infezioni in Medicina
|January 1, 1996
PubMed

Insights

This study followed nine patients with AIDS and cryptococcosis. A combination antifungal treatment showed effectiveness in eradicating neurological infections and preventing relapses in most patients.

Area of Science:

  • Infectious Diseases
  • Mycology
  • Immunocompromised Hosts

Context:

  • Cryptococcosis is a significant opportunistic infection in patients with Acquired Immunodeficiency Syndrome (AIDS).
  • Meningoencephalitis and hematogenous spread are severe clinical presentations of cryptococcosis in AIDS patients.
  • Effective treatment strategies are crucial for managing cryptococcosis in this vulnerable population.

Purpose:

  • To report clinical and microbiological findings from a 6-month follow-up of AIDS patients with cryptococcosis.
  • To evaluate the efficacy of a specific antifungal regimen including Amphotericin B, Flucytosine, and Itraconazole.
  • To assess treatment outcomes, including relapse rates and prognostic factors.

Summary:

  • Nine patients with AIDS and cryptococcosis were treated with Amphotericin B plus Flucytosine, followed by Itraconazole for acute illness, and then chronic suppressive Itraconazole.
  • Seven patients had meningoencephalitis, and two had hematogenous infection.
  • While three meningoencephalitis cases showed eradication and no relapse, two patients with cerebral granulomas had poor prognosis. Two non-neurological cases did not relapse.

Impact:

  • The findings highlight the potential efficacy of a multi-drug regimen for treating cryptococcosis in AIDS patients, particularly for neurological forms.
  • Identifying prognostic factors like cerebral granulomas is crucial for patient management.
  • This study contributes to understanding long-term outcomes and guiding therapeutic approaches for cryptococcosis in immunocompromised individuals.

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...